Agenda
9:00 AM | Addiction
Fighting the pandemic within the pandemic
John Bencich, Chief Executive Officer | Achieve Life Sciences (ACHV)
William Stilley, Chief Executive Officer | Adial Pharmaceuticals (ADIL)
Celia Morgan, PhD., Head of Ketamine Assisted Psychotherapy for Addiction | Awakn Life Sciences (NEO:AWKN, OTC: AWKNF)
Rakesh Jetly FRCPC, M.D., Chief Medical Officer | Mydecine Innovations Group (NEO:MYCO, OTC: MYCOF)
Robert Stein, MD, PhD., Chief Medical Officer | Protagenic Therapeutics (PTIX)
10:00 AM | Next Gen Psychedelics: Novel Chemical Entities
Can drug discovery improve psychedelics with shorter acting, better targeted compounds?
Dr. Shaun McNulty, Chief Scientific Officer | Awakn Life Sciences (NEO:AWKN, OTC: AWKNF)
Nathan Bryson, PhD, Chief Scientific Officer | Field Trip Health (FTRP)
James Lanthier, Chief Executive Officer | Mindset Pharma (CSE: MSET, OTC: MSSTF)
Joseph Tucker, PhD, as part of incoming MagicMed, acquired by Enveric | Enveric Biosciences (ENVB)
Rob Roscow, Chief Scientific Officer | Mydecine Innovations Group (NEO:MYCO, OTC: MYCOF)
12:00 PM | Clinics and Commercialization
Scaling psychedelics to meet the needs of the mental health space
Anthony Tennyson, Chief Executive Officer | Awakn Life Sciences (NEO:AWKN, OTC: AWKNF)
Joseph del Moral, Chief Executive Officer | Field Trip Health (FTRP)
Marco Mohwinckel, Chief Commercial Officer | COMPASS Pathways (CMPS)
Robert Barrow, Chief Executive Officer | Mind Medicine (MindMed) (MNMD)
1:00 PM | The Second Generation- Beyond Psilocybin and MDMA
LSD, DMT, Ibogaine, and more – a look beyond the first wave of psychedelic compounds
Robert Barrow, Chief Executive Officer | Mind Medicine (MindMed) (MNMD)
Danny Talati, Director, Business Development | Atai Life Sciences (ATAI)
Kelsey Ramsden, Chief Executive Officer | Mind Cure Health (CNSX:MCUR, OTC: MCURF)
Carol Routledge, PhD., CMO & CSO | Small Pharma (TSXV: DMT, OTC: DMTTF)
2:00 PM | Depression
Spravato opened the door, what comes next?
Guy Goodwin MD, Chief Medical Officer | COMPASS Pathways (CMPS)
Robert Stein, MD, PhD., Chief Medical Offic | Protagenic Therapeutics (PTIX)
Raj Mehra, PhD., Chief Executive Officer | Seelos Therapeutics (SEEL)
Peter Rands, Chief Executive Officer | Small Pharma (TSXV: DMT, OTC: DMTTF)
3:00 PM | Delivery, Manufacturing, & Technology
What does it take to succeed in Psychedelics beyond drugs and clinics
Josh Bartch, Chief Executive Officer | Mydecine Innovations Group (NEO:MYCO, OTC: MYCOF)
Evan Levine, Chief Executive Officer | PsyBio Therapeutics (TXV: PSYB, PSYBF)
Philip Young, Chief Executive Officer | Lobe Sciences (CNSX: LOBE, OTC: GTSIF)
Kelsey Ramsden, Chief Executive Officer | Mind Cure Health (CNSX:MCUR, OTC: MCURF)
Fabio Chianelli, Chief Executive Officer | PharmaTher Holdings (CNSX: PHRM, OTC: PHRRF)
4:00 PM | Keynote and Q&A
Rick Doblin, PhD, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS)
